Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people
Author:
- MRC/BHF Heart Protection Study Collaborative GroupMGMRC/BHF Heart Protection Study Collaborative Group
Open Access
- 31 March 2009
- journal article
- clinical trial
- Published by Springer Nature in BMC Clinical Pharmacology
- Vol. 9 (1) , 6
Abstract
Background: Simvastatin reduces cardiovascular mortality and morbidity but, as with other HMG-CoA reductase inhibitors, can cause significant muscle toxicity and has been associated with elevations of liver transaminases. Methods: Muscle and liver adverse effects of simvastatin 40 mg daily were evaluated in a randomized placebo-controlled trial involving 20,536 UK patients with vascular disease or diabetes (in which a substantial reduction of cardiovascular mortality and morbidity has previously been demonstrated). Results: The excess incidence of myopathy in the simvastatin group was < 0.1% over the 5 years of the trial, and there were no significant differences between the treatment groups in the incidence of serious hepatobiliary disease. Conclusion: Among the many different types of high-risk patient studied (including women, older individuals and those with low cholesterol levels), there was a very low incidence (< 0.1%) of myopathy during 5 years treatment with simvastatin 40 mg daily. The risk of hepatitis, if any, was undetectable even in this very large long-term trial. Routine monitoring of liver function tests during treatment with simvastatin 40 mg is not useful. Trial Registration: ISRCTN48489393Keywords
This publication has 25 references indexed in Scilit:
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12 064 myocardial infarction survivorsAmerican Heart Journal, 2007
- Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditionsJournal of Vascular Surgery, 2007
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Statin Safety: An Overview and Assessment of the Data—2005The American Journal of Cardiology, 2006
- Simvastatin: a reviewExpert Opinion on Pharmacotherapy, 2004
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- The liver and lovastatinThe American Journal of Cardiology, 2002
- Estimating the effect of the run‐in on the power of the physicians' health studyStatistics in Medicine, 1991
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988